Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05049798
Registration number
NCT05049798
Ethics application status
Date submitted
31/08/2021
Date registered
20/09/2021
Titles & IDs
Public title
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
Query!
Scientific title
Assessment of Guselkumab (Tremfya) and IL-17 Inhibitor Therapies in Patients With Psoriatic Arthritis in Routine Clinical Practice; A Prospective, Observational Cohort Study
Query!
Secondary ID [1]
0
0
CNTO1959PSA4001
Query!
Secondary ID [2]
0
0
CR108938
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PsABIOnd
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Psoriatic
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Guselkumab
Treatment: Drugs - IL-17i
Cohort 1: Guselkumab - Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
Cohort 2: Interleukin-17 inhibitor (IL-17i) - Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
Treatment: Drugs: Guselkumab
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
Treatment: Drugs: IL-17i
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Start and Stop Date of Guselkumab, as Applicable, For Each Participant
Query!
Assessment method [1]
0
0
The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence.
Query!
Timepoint [1]
0
0
Up to 39 months
Query!
Primary outcome [2]
0
0
The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant
Query!
Assessment method [2]
0
0
The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence.
Query!
Timepoint [2]
0
0
Up to 39 months
Query!
Secondary outcome [1]
0
0
Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively
Query!
Assessment method [1]
0
0
Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet.
Query!
Timepoint [1]
0
0
Baseline up to 39 months
Query!
Secondary outcome [2]
0
0
Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA)
Query!
Assessment method [2]
0
0
The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter \[mm\]) to "extremely active PsA" (100 mm).
Query!
Timepoint [2]
0
0
Baseline up to 39 months
Query!
Secondary outcome [3]
0
0
Change from Baseline in Assessment of Dactylitis
Query!
Assessment method [3]
0
0
The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented.
Query!
Timepoint [3]
0
0
Baseline up to 39 months
Query!
Secondary outcome [4]
0
0
Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI)
Query!
Assessment method [4]
0
0
The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right).
Query!
Timepoint [4]
0
0
Baseline up to 39 months
Query!
Secondary outcome [5]
0
0
Change from Baseline in Nail Involvement
Query!
Assessment method [5]
0
0
Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes.
Query!
Timepoint [5]
0
0
Baseline up to 39 months
Query!
Secondary outcome [6]
0
0
Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement
Query!
Assessment method [6]
0
0
The BSA score indicates the surface area of the participant's body effected by psoriasis.
Query!
Timepoint [6]
0
0
Baseline up to 39 months
Query!
Secondary outcome [7]
0
0
Change from Baseline in C-reactive Protein (CRP)
Query!
Assessment method [7]
0
0
Change from baseline in CRP will be reported.
Query!
Timepoint [7]
0
0
Baseline up to 39 months
Query!
Secondary outcome [8]
0
0
Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA)
Query!
Assessment method [8]
0
0
Change from Baseline in MDA/VLDA will be reported.
Query!
Timepoint [8]
0
0
Baseline up to 39 months
Query!
Secondary outcome [9]
0
0
Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA)
Query!
Assessment method [9]
0
0
DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.
Query!
Timepoint [9]
0
0
Baseline up to 39 months
Query!
Secondary outcome [10]
0
0
Response as a Measure of Clinical Improvement in cDAPSA/DAPSA
Query!
Assessment method [10]
0
0
Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.
Query!
Timepoint [10]
0
0
Up to 39 months
Query!
Secondary outcome [11]
0
0
Start and Stop Dates of All Treatments and the Sequence of Treatment Lines
Query!
Assessment method [11]
0
0
Start and stop dates of all treatments and the sequence of treatment lines will be reported.
Query!
Timepoint [11]
0
0
Up to 39 months
Query!
Secondary outcome [12]
0
0
Percentage of Participants with Adverse Events (AEs)
Query!
Assessment method [12]
0
0
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Query!
Timepoint [12]
0
0
Up to 39 months
Query!
Secondary outcome [13]
0
0
BSA PSO Skin Involvement
Query!
Assessment method [13]
0
0
The BSA score indicates the surface area of the participant's body affected by psoriasis.
Query!
Timepoint [13]
0
0
Up to 39 months
Query!
Secondary outcome [14]
0
0
Rheumatic Disease Comorbidity Index
Query!
Assessment method [14]
0
0
Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported.
Query!
Timepoint [14]
0
0
Up to 39 months
Query!
Secondary outcome [15]
0
0
Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST)
Query!
Assessment method [15]
0
0
FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain.
Query!
Timepoint [15]
0
0
Baseline up to 6 months
Query!
Secondary outcome [16]
0
0
Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L)
Query!
Assessment method [16]
0
0
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems.
Query!
Timepoint [16]
0
0
Baseline up to 39 months
Query!
Secondary outcome [17]
0
0
Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Query!
Assessment method [17]
0
0
The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area.
Query!
Timepoint [17]
0
0
Baseline up to 39 months
Query!
Secondary outcome [18]
0
0
Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12)
Query!
Assessment method [18]
0
0
PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).
Query!
Timepoint [18]
0
0
Baseline up to 39 months
Query!
Secondary outcome [19]
0
0
Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores
Query!
Assessment method [19]
0
0
The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week.
Query!
Timepoint [19]
0
0
Baseline up to 39 months
Query!
Secondary outcome [20]
0
0
Change from Baseline in Pain VAS Score
Query!
Assessment method [20]
0
0
The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm).
Query!
Timepoint [20]
0
0
Baseline up to 39 months
Query!
Secondary outcome [21]
0
0
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Query!
Assessment method [21]
0
0
BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity.
Query!
Timepoint [21]
0
0
Baseline up to 39 months
Query!
Secondary outcome [22]
0
0
Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP)
Query!
Assessment method [22]
0
0
The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value.
Query!
Timepoint [22]
0
0
Baseline up to 39 months
Query!
Secondary outcome [23]
0
0
Change from Baseline in Dermatology Life Quality Index (DLQI)
Query!
Assessment method [23]
0
0
The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant.
Query!
Timepoint [23]
0
0
Baseline up to 39 months
Query!
Secondary outcome [24]
0
0
Change from Baseline in Patient Acceptable Symptom State (PASS)
Query!
Assessment method [24]
0
0
The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being.
Query!
Timepoint [24]
0
0
Baseline up to 39 months
Query!
Secondary outcome [25]
0
0
Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA)
Query!
Assessment method [25]
0
0
The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Query!
Timepoint [25]
0
0
Baseline up to 39 months
Query!
Secondary outcome [26]
0
0
Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
Query!
Assessment method [26]
0
0
TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication.
Query!
Timepoint [26]
0
0
Baseline up to 39 months
Query!
Secondary outcome [27]
0
0
Number of Participants Switching or Stopping Treatment
Query!
Assessment method [27]
0
0
Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported.
Query!
Timepoint [27]
0
0
Up to 39 months
Query!
Eligibility
Key inclusion criteria
Main study:
* Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR)
* Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection
* Sign a participation agreement/Informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
* Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments
* The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
Substudy:
* Must sign the substudy ICF allowing data collection in accordance with local requirements
* Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study
* Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Main study:
* Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment
* Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again
* Unwilling or unable to participate in long-term data collection
* Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent)
* Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable)
Substudy:
* Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site
* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment
* Unwilling or unable to comply with substudy assessments
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/08/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
6/12/2027
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1314
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
The Queen Elizabeth Hospital - Adelaide
Query!
Recruitment hospital [2]
0
0
Footscray Hospital, Western Health - Footscray
Query!
Recruitment hospital [3]
0
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment postcode(s) [1]
0
0
5011 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Footscray
Query!
Recruitment postcode(s) [3]
0
0
2065 - St Leonards
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Buenos Aires
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [3]
0
0
Argentina
Query!
State/province [3]
0
0
Córdoba
Query!
Country [4]
0
0
Argentina
Query!
State/province [4]
0
0
San Fernando Buenos Aires
Query!
Country [5]
0
0
Austria
Query!
State/province [5]
0
0
Graz
Query!
Country [6]
0
0
Austria
Query!
State/province [6]
0
0
Linz
Query!
Country [7]
0
0
Austria
Query!
State/province [7]
0
0
Vienna
Query!
Country [8]
0
0
Austria
Query!
State/province [8]
0
0
Wien
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Brugge
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Brussel
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Genk
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Leuven
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Liège
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
British Columbia
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Manitoba
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Nova Scotia
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Ontario
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Quebec
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Saskatchewan
Query!
Country [20]
0
0
Colombia
Query!
State/province [20]
0
0
Bogota
Query!
Country [21]
0
0
Colombia
Query!
State/province [21]
0
0
Bucaramanga
Query!
Country [22]
0
0
Colombia
Query!
State/province [22]
0
0
Medellin
Query!
Country [23]
0
0
Colombia
Query!
State/province [23]
0
0
Medellín
Query!
Country [24]
0
0
Colombia
Query!
State/province [24]
0
0
Montería
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Bobigny
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Cholet
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Clermont Ferrand
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Creteil
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Echirolles
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Lille
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Lyon
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Nice
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Orléans
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Paris
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Strasbourg Cedex
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Toulouse
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Amberg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bayreuth
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Berlin
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Dusseldorf
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Erfurt
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Frankfurt
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Halle-Saale
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Hamburg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Herne
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Koln
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Leipzig
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Magdeburg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
München
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Neubrandenburg
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Püttlingen
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Ratingen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Templin
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Vogelsang-Gommern
Query!
Country [55]
0
0
Greece
Query!
State/province [55]
0
0
Athens
Query!
Country [56]
0
0
Greece
Query!
State/province [56]
0
0
Ioannina
Query!
Country [57]
0
0
Greece
Query!
State/province [57]
0
0
Patras
Query!
Country [58]
0
0
Greece
Query!
State/province [58]
0
0
Patra
Query!
Country [59]
0
0
Greece
Query!
State/province [59]
0
0
Thessaloniki
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Bari
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Campobasso
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Catanzaro
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Firenze
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Napoli
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Palermo
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Pisa
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Potenza
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Rome
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Rozzano
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Torino
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Udine
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Verona
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Hyogo
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Meguro-ku
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Osaka
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Sapporo
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Tokyo
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Cheonan-si
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Seongnam
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Seoul
Query!
Country [81]
0
0
Mexico
Query!
State/province [81]
0
0
Merida
Query!
Country [82]
0
0
Mexico
Query!
State/province [82]
0
0
Mexico
Query!
Country [83]
0
0
Mexico
Query!
State/province [83]
0
0
Zapopan
Query!
Country [84]
0
0
Netherlands
Query!
State/province [84]
0
0
Amsterdam
Query!
Country [85]
0
0
Netherlands
Query!
State/province [85]
0
0
Enschede
Query!
Country [86]
0
0
Netherlands
Query!
State/province [86]
0
0
Groningen
Query!
Country [87]
0
0
Netherlands
Query!
State/province [87]
0
0
Helmond
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Kemerovo
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Moscow
Query!
Country [90]
0
0
Russian Federation
Query!
State/province [90]
0
0
Tomsk
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
A Coruna
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Algeciras / Cadiz
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Barcelona
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Bilbao
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Cordoba
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Granada
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Madrid
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Oviedo
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Santiago de Compostela
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Sevilla
Query!
Country [101]
0
0
Sweden
Query!
State/province [101]
0
0
Göteborg
Query!
Country [102]
0
0
Sweden
Query!
State/province [102]
0
0
Lund
Query!
Country [103]
0
0
Sweden
Query!
State/province [103]
0
0
Orebro
Query!
Country [104]
0
0
Sweden
Query!
State/province [104]
0
0
Stockholm
Query!
Country [105]
0
0
Sweden
Query!
State/province [105]
0
0
Uppsala
Query!
Country [106]
0
0
Switzerland
Query!
State/province [106]
0
0
Fribourg
Query!
Country [107]
0
0
Taiwan
Query!
State/province [107]
0
0
Kaohsiung
Query!
Country [108]
0
0
Taiwan
Query!
State/province [108]
0
0
Taichung
Query!
Country [109]
0
0
United Kingdom
Query!
State/province [109]
0
0
Aberdeen
Query!
Country [110]
0
0
United Kingdom
Query!
State/province [110]
0
0
Abergavenny
Query!
Country [111]
0
0
United Kingdom
Query!
State/province [111]
0
0
Airdrie
Query!
Country [112]
0
0
United Kingdom
Query!
State/province [112]
0
0
Barnet
Query!
Country [113]
0
0
United Kingdom
Query!
State/province [113]
0
0
Bath
Query!
Country [114]
0
0
United Kingdom
Query!
State/province [114]
0
0
Glasgow
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
Hull
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Leeds
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Manchester
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Newcastle Upon Tyne
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Portsmouth
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Salford
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Southampton
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Staffordshire
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Stamford
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Wishaw
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Pharmaceutica N.V., Belgium
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
Query!
Trial website
https://clinicaltrials.gov/study/NCT05049798
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Pharmaceutica N.V., Belgium Clinical Trial
Query!
Address
0
0
Janssen Pharmaceutica N.V., Belgium
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05049798